Full approval of lecanemab to treat Alzheimer’s by the FDA fails patients and the public, consumer group says
July 11, 2023
The approval of a new drug to treat Alzheimer’s disease is controversial. The U.S. Food and Drug Administration gave full approval to the drug lecanemab (Leqembi) Thursday to treat adults with Alzheimer’s disease. In January, Public Citizen, a consumer advocacy organization, urged the agency not to approve the drug. Read more →